Retatrutide Regulatory Status: Federal Compounding Prohibition

Current status: Retatrutide is investigational and not FDA-approved. It is not available for public use; federal law does not permit it to be compounded, and HealthRX does not offer it.

Current research status

No state or commercial program changes retatrutide's federal investigational status. Lilly states that the medicine has not been approved by any regulatory agency [1]. The FDA states that retatrutide cannot be used in compounding under federal law [2].

What researchers are studying

Retatrutide is a single molecule that activates GIP, GLP-1, and glucagon receptors. The published phase 2 obesity trial enrolled 338 adults and reported dose-dependent body-weight changes over 48 weeks, alongside gastrointestinal adverse events and increases in heart rate that require continued study [3].

Lilly's phase 3 program evaluates efficacy and safety in obesity and overweight, type 2 diabetes, obstructive sleep apnea, knee osteoarthritis pain, cardiovascular and renal outcomes, chronic low back pain, and metabolic liver disease [1]. Trial findings do not create a public treatment pathway; regulatory review and an approval decision must occur first.

Interpreting the evidence

Clinical-trial results describe outcomes in defined research populations under protocol monitoring. They do not establish instructions for self-treatment, and cross-trial comparisons cannot substitute for head-to-head studies. Larger and longer studies are needed to clarify durability, uncommon adverse events, and outcomes across diverse populations.

Registered retatrutide studies, recruitment status, and eligibility criteria are published on ClinicalTrials.gov. Participation is determined by each study team and is not a public prescription or sales pathway [4].